Discussion of concerns with molnupiravir and the MOVe-OUT trial. Author notes that results showing bone marrow toxicity in dogs were mentioned in this preprint , but removed from the journal version . Some additional details were provided by the UK regulator:
“Reversible, dose-related bone marrow toxicity affecting all haematopoietic cell lines was observed in dogs at ≥17 mg/kg/day (0.4 times the human NHC exposure at the recommended human dose (RHD)).” 
For those without TrialSite News access, this article can also be found at .
Goldstein et al., 11/6/2021, preprint, 1 author.